ACR Meeting Abstracts

ACR Meeting Abstracts

Abstract Number: 0874

Impact of Deucravacitinib on Disease Activity in Patients With Psoriatic Arthritis (PsA): Results From the Pivotal Phase 3 PsA Studies

Atul Deodhar1, Ricardo Blanco2, Arthur Kavanaugh3, Alice Gottlieb4, Laura Coates5, Christopher Ritchlin6, Alan Kivitz7, Xiaofeng Zeng8, Akimichi Morita9, Diamant Thaçi10, Stefan Varga11, Kexuan Li11, Ying-Ming Jou12, Eleni Vritzali13 and Philip J. Mease14, 1Division of Arthritis and Rheumatic Diseases, Oregon Health & Science University, Portland, OR, 2Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain, 3University of California, San Diego, School of Medicine, San Diego, CA, 4Department of Dermatology, UT Southwestern Medical Center, Dallas, TX, 5Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, England, United Kingdom, 6University of Rochester Medical Center, Canandaigua, NY, 7Altoona Center for Clinical Research, Duncansville, PA, 8Department of Rheumatology, Peking Union Medical College Hospital (PUMCH), Chinese Academy of Medical Sciences National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Beijing, China (People's Republic), 9Department of Geriatric and Environmental Dermatology, Graduate School of Medical Sciences, Nagoya City University, Nagoya, Japan, 10Institute and Comprehensive Center for Inflammation Medicine, University of Lübeck, Lübeck, Germany, 11Bristol Myers Squibb, Princeton, NJ, 12Bristol Myers Squibb, Princeton, 13Bristol Myers Squibb, Boudry, Switzerland, 14Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA

Meeting: ACR Convergence 2025

Keywords: , , , ,

Session Information

Date: Monday, October 27, 2025

Title: Abstracts: Spondyloarthritis Including Psoriatic Arthritis – Treatment I: Therapies (0873–0878)

Session Type: Abstract Session

Session Time: 10:15AM-10:30AM

Background/Purpose: The first-in-class, oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor deucravacitinib has an established clinical profile in moderate to severe plaque psoriasis with over 5 years of long-term data1 and is approved in multiple countries for this indication. Deucravacitinib showed superior efficacy vs placebo (PBO) at W16 across multiple endpoints in patients (pts) with active PsA in the global, randomized, double-blind, PBO-controlled phase 3 POETYK PsA-1 (NCT04908202) and PsA-2 (NCT04908189) studies, with no new safety signals.2,3 Composite efficacy measures provide a comprehensive assessment of disease activity and response to treatment across several disease domains. We report deucravacitinib efficacy based on composite measures of disease activity in pts from the POETYK PsA studies.

Methods: Pts in the POETYK PsA-1 and PsA-2 studies were randomized to deucravacitinib 6 mg once daily or PBO for 16 weeks (in PsA-2, a group received apremilast as a safety reference arm). This analysis included pts treated with deucravacitinib or PBO to W16. Composite measures of disease activity, including minimal disease activity (MDA), Disease Activity in Psoriatic Arthritis (DAPSA), Psoriatic Arthritis Disease Activity Score (PASDAS), modified Composite Psoriatic Disease Activity Index (mCPDAI), and Psoriatic Arthritis Response Criteria (PsARC), were analyzed using nonresponder imputation for missing binary data and control-based pattern imputation for missing continuous data.

Results: At W16, a significantly higher proportion of pts treated with deucravacitinib vs PBO achieved MDA response (PsA-1, P = 0.0012; PsA-2, P = 0.0007), DAPSA low disease activity or remission (PsA-1, P = 0.0001; PsA-2, P < 0.0001), DAPSA disease remission (PsA-1, P = 0.0009; PsA-2, P = 0.0005), and PsARC response (PsA-1, P < 0.0001; PsA-2, P < 0.0001; Figure 1). Decrease from baseline in PASDAS and mCPDAI at W16 was significantly greater in pts treated with deucravacitinib vs PBO (PASDAS: PsA-1, P < 0.0001; PsA-2, P < 0.0001; mCPDAI: PsA-1, P < 0.0001; PsA-2, P < 0.0001; Figure 2). Efficacy was consistently higher with deucravacitinib vs PBO in male and female pts.

Conclusion:

Conclusion: In these analyses of the pivotal POETYK PsA-1 and PsA-2 phase 3 studies, deucravacitinib substantially reduced disease activity vs PBO at W16 in several composite measures of disease activity, and a significantly higher proportion of pts reached optimal control of disease activity, which aligns with the results from the primary analyses.2,3 Given that remission and low disease activity are primary goals of PsA treatment, deucravacitinib may be an efficacious treatment choice for pts with active PsA.ReferencesArmstrong AW, et al. J of Skin. 2025;9:s532.Mease PJ, et al. Presented at the 2025 American Academy of Dermatology Annual Meeting; March 7-11, 2025; Orlando, FL. Abstract 66894.Bristol Myers Squibb. News Release. Accessed April 21, 2025. https://news.bms.com/news/details/2024/Bristol-Myers-Squibb-Announces-Positive-Topline-Results-from-Two-Pivotal-Phase-3-Trials-Evaluating-Sotyktu-deucravacitinib-in-Adults-with-Psoriatic-Arthritis/default.aspx.

Supporting image 1

Supporting image 2

Disclosures: A. Deodhar: BMS, 2, 5, Eli Lilly and Company, 2, 5, 6, J&J, 2, 5, 6, MoonLake Immunotherapeutics, 2, Novartis, 2, 5, 6, Pfizer, 2, 5, 6, UCB, 2, 5, 6; R. Blanco: AbbVie/Abbott, 2, 5, 6, Bristol-Myers Squibb(BMS), 2, 6, Eli Lilly, 2, 6, Janssen, 2, 6, Merck/MSD, 2, 5, 6, Pfizer, 2, 6, Roche, 2, 5, 6; A. Kavanaugh: Amgen, 2, Bristol-Myers Squibb(BMS), 2, Eli Lilly, 2, 5, GRAPPA, 12, Co-President, Janssen, 2, 5, MoonLake Immunotherapeutics, 2, Pfizer, 2, 5, Takeda, 2, UCB, 2; A. Gottlieb: Amgen, 1, 2, 6, Avalo Therapeutics, 5, Bristol Myers Squibb, 5, Eli Lilly, 1, 2, 6, Highlights Therapeutics, 1, 2, 6, MoonLake, 5, Novartis, 1, 2, 6, Sanofi, 1, 2, 6, Sun Pharma, 1, 2, 6, Takeda, 1, 2, 6, Teva, 1, 2, 6, UCB, 1, 2, 5, 6, Xbiotech, 1, 2, 6; L. Coates: AbbVie, 2, 5, 6, Amgen, 2, 5, 6, Biogen, 6, BMS, 2, Boehringer Ingelheim, 2, Celgene, 2, 5, 6, Domain, 2, Eli Lilly and Company, 2, 5, 6, Galapagos, 2, 6, Gilead, 2, 5, 6, GSK, 6, Janssen, 2, 5, 6, Medac, 6, MoonLake Immunotherapeutics, 2, Novartis, 2, 5, 6, Pfizer, 2, 5, 6, UCB, 2, 5, 6; C. Ritchlin: AbbVie, 2, Amgen, 2, Bristol-Myers Squibb(BMS), 2, Eli Lilly, 2, Janssen, 2, 5, MoonLake Pharma, 2, Novartis, 2, 5, Solara, 2, UCB, 2; A. Kivitz: AbbVie/Abbott, 2, 6, Amgen, 6, 11, Coval, 2, EcoR1, 2, Eli Lilly, 6, Fresenius Kabi, 1, 2, Genzyme, 12, Scientific expert fees, Gilead, 2, 11, GlaxoSmithKlein(GSK), 2, 6, 11, Grünenthal, 2, Halia, 2, Horizon, 1, 2, Innovaderm, 2, Janssen, 1, 2, Novartis, 1, 11, Pacira, 2, Pfizer, 6, 11, Prime, 6, Princeton Biopartners, 1, Prometheus, 2, Sanofi-Regeneron, 6, Santa Ana Bio Inc, 2, Selecta, 2, SynAct, 2, Takeda, 2, UCB, 1, 2, 6, XBiotech, 2; X. Zeng: None; A. Morita: AbbVie/Abbott, 2, 5, 6, Amgen, 2, 5, 6, Boehringer-Ingelheim, 2, 5, 6, Bristol-Myers Squibb(BMS), 2, 5, 6, Eli Lilly, 2, 5, 6, Janssen, 2, 5, 6, Kyowa Kirin, 2, 5, 6, LEO Pharma, 2, 5, 6, Maruho, 2, 5, 6, Sun Pharma Japan, 2, 5, 6, Taiho Pharmaceutical, 2, 5, 6, Torii Pharmaceutical, 2, 5, 6, UCB Japan, 2, 5, 6, Ushio, 2, 5, 6; D. Thaçi: AbbVie, 1, 2, 5, 12, Investigator, Almirall, 1, 2, 12, Investigator, Amgen, 1, 2, 12, Investigator, Boehringer-Ingelheim, 1, 2, 12, Investigator, Bristol Myers Squibb, 1, 2, 12, Investigator, Celltrion, 1, 2, 12, Investigator, Eli Lilly and Company, 1, 2, 12, Investigator, Fresenius-Kabi, 2, 5, Galderma, 1, 2, 12, Investigator, Johnson & Johnson, 1, 2, 12, Investigator, Kyowa Kirin, 1, 2, 12, Investigator, L’Oreal, 1, 2, 12, Investigator, LEO Pharma, 1, 2, 5, 12, Investigator, New Bridge, 1, 2, 12, Investigator, Novartis, 1, 2, 12, Investigator, Pfizer, 1, 2, 12, Investigator, Regeneron, 1, 2, 12, Investigator, Samsung, 1, 2, 12, Investigator, Sanofi, 1, 2, 12, Investigator, Sun-Pharma, 1, 2, 5, Target-RWE, 1, 2, 12, Investigator, UCB, 1, 2, 12, Investigator, Vichy, 1, 2, 12, Investigator; S. Varga: Bristol Myers Squibb, 3, 11; K. Li: Bristol-Myers Squibb(BMS), 3, 11; Y. Jou: Bristol Myers Squibb, 3, 11; E. Vritzali: Bristol Myers Squibb, 3, 11; P. Mease: AbbVie, 2, 5, 6, Acelyrin, 2, 5, Amgen, 2, 5, 6, BMS, 2, 5, Century, 2, Cullinan, 2, Eli Lilly and Company, 2, 5, 6, Inmagene, 2, J&J Innovative Medicine, 2, 5, 6, MoonLake Immunotherapeutics, 2, Novartis, 2, 5, 6, Pfizer, 2, 5, 6, Sana, 5, Spyre, 5, Takeda, 2, UCB, 2, 5, 6.

To cite this abstract in AMA style:

Deodhar A, Blanco R, Kavanaugh A, Gottlieb A, Coates L, Ritchlin C, Kivitz A, Zeng X, Morita A, Thaçi D, Varga S, Li K, Jou Y, Vritzali E, Mease P. Impact of Deucravacitinib on Disease Activity in Patients With Psoriatic Arthritis (PsA): Results From the Pivotal Phase 3 PsA Studies [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/impact-of-deucravacitinib-on-disease-activity-in-patients-with-psoriatic-arthritis-psa-results-from-the-pivotal-phase-3-psa-studies/. Accessed .

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/impact-of-deucravacitinib-on-disease-activity-in-patients-with-psoriatic-arthritis-psa-results-from-the-pivotal-phase-3-psa-studies/